Cargando…
Erratum to miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622493/ https://www.ncbi.nlm.nih.gov/pubmed/36330407 http://dx.doi.org/10.21037/atm-2022-34 |
Ejemplares similares
-
miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1
por: Tan, Wenliang, et al.
Publicado: (2021) -
Erratum to “miR-876 Inhibits EMT and Liver Fibrosis via POSTN to Suppress Metastasis in Hepatocellular Carcinoma”
por: Chen, Kai, et al.
Publicado: (2020) -
Icariside II ameliorates endothelial dysfunction by regulating the MAPK pathway via miR-126/SPRED1 in diabetic human cavernous endothelial cells
por: Lei, Hongen, et al.
Publicado: (2018) -
miR-126-5p affects the chemosensitivity of colorectal cancer cells by regulating SPRED1, ERK1/2 pathway and apoptosis
por: Xu, Mingshi, et al.
Publicado: (2022) -
Erratum to “Durable Objective Response to Sorafenib and Role of Sequential
Treatment in Unresectable Hepatocellular Carcinoma”
Publicado: (2022)